Skip to main content

Table 3 Fold-change of proteins in isomorellin- and/or doxorubicin-treated cells vs. DMSO-treated KKU-M156 cells

From: Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

   KKU-M156 cell
Proteins Treatments Fold-changes of proteins in treated vs. control cells
   Concentration of isomorellin or doxorubicin (μM)
  Isomorellin 0.06 0.12 0.25
Doxorubicin 0.007 0.015 0.031
Iso + Dox C1 C2 C3
Bcl-2 Isomorellin 0.83a 0.83a 0.76a
  Doxorubicin 1.00 0.95 0.82a
  Iso + Dox 0.84a 0.80b,–,* 0.41c,*,*
Bax Isomorellin 1.26 1.32c 1.32c
  Doxorubicin 1.20 1.33c 1.45c
  Iso + Dox 1.84b 1.93c,*,* 2.13c,*,*
Bax/Bcl-2 Isomorellin 0.48c 0.50b 0.50b
  Doxorubicin 0.35c 0.40b 0.51b
  Iso + Dox 0.62c 1.09–,*,* 2.35c,*,*
Survivin Isomorellin 1.00 0.96 0.86
  Doxorubicin 0.96 0.96 0.95
  Iso + Dox 0.96 0.64b,*,* 0.02c,*,*
Procaspase-9 Isomorellin 0.88 0.84 0.74a
  Doxorubicin 0.87 0.82 0.76a
  Iso + Dox 0.82a 0.57b,*,* 0.39b,*,*
Activated Isomorellin 10.00c 18.00c 30.00c
caspase-9  Doxorubicin 10.00c 20.00c 24.00c
  Iso + Dox 20.00c 64.00c,*,* 73.00c,*,*
Procaspase-3 Isomorellin 1.00 0.93 0.84
  Doxorubicin 1.00 0.93 0.86a
  Iso + Dox 0.93 0.68a,*,* 0.67b,*,*
Activated Isomorellin 8.00c 10.00c 20.00c
caspase-3 Doxorubicin 8.00c 9.00c 12.00c
  Iso + Dox 1.00 32.00c,*,* 36.00c,*,*
IκB-α Isomorellin 1.16a 1.18 1.25b
  Doxorubicin 1.16a 1.17 1.21b
  Iso + Dox 1.17 1.21 1.40a,*,*
pIκB-α Isomorellin 0.93 0.87 0.02a
  Doxorubicin 0.96 0.78 0.02b
  Iso + Dox 0.85a 0.73a,*,– 0.02b
NF-κB/p65 Isomorellin 1.00 0.77a 0.01c
  Doxorubicin 1.00 1.00 0.87a
  Iso + Dox 0.66b 0.02c,*,* 0.01c,–,*
MRP1 Isomorellin 0.97 0.91 0.79b
  Doxorubicin 0.97 0.96 0.57b
  Iso + Dox 0.81a 0.79a,–,* 0.35c,*,*
  1. Data = The mean ratio of the density readings of target proteins normalized to β-actin from the isomorellin- and/or doxorubicin-treated to DMSO-treated cells (n = 3). aP < 0.05, bP < 0.01, cP < 0.001 vs. DMSO-treated cells. Comparison between isomorellin or doxorubicin treatment alone and combined drug treatment indicated by *,*P < 0.05 respectively, not significant difference indicated by “”.